NF Trinity Capital Hong Kong Ltd Has $20.52 Million Stake in Allergan plc (AGN)
NF Trinity Capital Hong Kong Ltd grew its stake in Allergan plc (NYSE:AGN) by 14.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 125,448 shares of the company’s stock after buying an additional 16,000 shares during the quarter. Allergan accounts for 2.7% of NF Trinity Capital Hong Kong Ltd’s holdings, making the stock its 10th biggest position. NF Trinity Capital Hong Kong Ltd’s holdings in Allergan were worth $20,521,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. Cable Hill Partners LLC boosted its holdings in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the last quarter. Rockefeller Financial Services Inc. boosted its holdings in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the last quarter. BB&T Investment Services Inc. boosted its holdings in Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after purchasing an additional 641 shares during the last quarter. Phocas Financial Corp. acquired a new position in Allergan during the second quarter worth $150,000. Finally, Acropolis Investment Management LLC acquired a new position in Allergan during the fourth quarter worth $153,000. Institutional investors own 80.23% of the company’s stock.
In related news, Director Chris W. Bodine acquired 3,030 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were bought at an average cost of $164.77 per share, with a total value of $499,253.10. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Brent L. Saunders purchased 4,600 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders bought 17,630 shares of company stock worth $2,890,057 over the last three months. Insiders own 0.36% of the company’s stock.
Allergan plc (NYSE:AGN) opened at $170.39 on Thursday. The firm has a market cap of $55,983.71, a PE ratio of -12.70, a PEG ratio of 1.24 and a beta of 1.19. Allergan plc has a 1 year low of $160.07 and a 1 year high of $256.80. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.90 earnings per share. sell-side analysts predict that Allergan plc will post 15.41 EPS for the current fiscal year.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.